Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK945237 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| GSK945237 | EXPERIMENTAL | Active Study Drug |
| Sugar Pill | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| GSK945237 | DRUG | - |
| Sugar Pill | DRUG | Placebo |
Inclusion Criteria: * Healthy male and female adults between 18 and 60 years of age. * Body weight proportional to height. * Female subjects must be of non-childbearing potential. * QTc less than 450 msec at screening Exclusion Criteria: * Any clinically relevant abnormality identified on the scr...
GSK945237 is an investigational small molecule antibacterial being developed by GSK plc for bacterial infections. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. It is not an approved medicine and remains in early clinical development.
GSK945237 is being developed for bacterial infections. The only recorded human study of GSK945237 enrolled healthy volunteers rather than patients, so it was designed to assess safety, tolerability and pharmacokinetics rather than to treat an active infection. Its use in patients has not been established.
GSK945237 is developed by GSK plc, which trades under the ticker GSK. The compound is an internally originated small molecule antibacterial candidate in the company's infectious disease pipeline.
GSK945237 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. As an investigational agent, GSK945237 has not been approved by the FDA or any other regulator for any indication.
GSK945237 has been evaluated in one completed Phase 1 trial, NCT00517673, titled a study to evaluate safety, tolerability, pharmacokinetics and food effect of single doses of GSK945237 in healthy subjects. It was a randomized, placebo-controlled trial that enrolled 68 healthy adults in Australia.
Yes. The completed Phase 1 trial NCT00517673 enrolled 68 healthy adult volunteers aged 18 years and older in Australia. It was randomized and placebo-controlled but not double-blind, and it assessed single doses of GSK945237 for safety, tolerability, pharmacokinetics and food effect.